

*Qidan Lixin Pill* 2.43 g/(kg·d), captopril group given captopril tablet 2.25 mg/(kg·d), and the other groups given 10 ml/(kg·d) of deionized water for intragastric administration. After 4 weeks, the cardiac hemodynamics indicators including heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum rate of increase in left ventricular pressure (+dp/dt max), maximum rate of decrease in left ventricular pressure (-dp/dt max) were detected. The left ventricular mass (LVM) was weighed, the left ventricular mass index (LVMI) calculated, and HE staining was used for pathological observation while Masson staining was used to calculate collagen volume fraction (CVF). The miR-133a, the expressions of mRNA and protein of transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) and connective tissue growth factor (CTGF) in each group were detected.

**Results** Compared with sham-operation group, the LVSP and +dp/dt max, -dp/dt max in model group were decreased while LVEDP was increased, LVMI and CVF increased, miR-133a decreased, and the expressions of mRNA and TGF- $\beta$ 1 and CTGF protein were increased ( $P < 0.01$ ). Compared with the model group, the LVSP and +dp/dt max, -dp/dt max in *Qidan Lixin Pill* group were increased while LVEDP was decreased, LVMI and CVF decreased, miR-133a increased, and the expressions of mRNA and TGF- $\beta$ 1 and CTGF protein were decreased ( $P < 0.05$  or  $P < 0.01$ ). The HE staining results showed that the residual myocardial fibers were disordered and partly fractured, and the muscle space was widened obviously in model group. The myocardial fibers in the peripheral areas of myocardial infarction were relatively regular in shape, and most of the cell membranes were basically complete in both captopril group and *Qidan Lixin Pill* group.

**Conclusion** *Qidan Lixin Pill* can prevent myocardial fibrosis in rats with myocardial infarction, and the intervention mechanism may be related to miR-133a/TGF- $\beta$ 1/CTGF signaling pathway.

**Keywords** myocardial infarction; myocardial fibrosis; *Qidan Lixin Pill*; transforming growth factor- $\beta$ 1; connective tissue growth factor; miR-133a

(收稿日期: 2018-06-14; 修回日期: 2018-08-08)

编辑: 邓 媛

## 第九届国际中医妇科学术大会参会通知 (第二轮通知)

由世界中医药学会联合会妇科专业委员会主办, 湖北福人药业股份有限公司协办的“第九届国际中医妇科学术大会”, 以“生殖障碍性疾病及妇科炎症性病变中医诊疗研究”为主题, 拟定于 2018 年 11 月 9—11 日在中国·湖北省武汉市举行, 届时将举办妇科炎症性病变中医诊疗高级论坛, 并设“福人杯”金刚藤胶囊有奖征文活动, 评选优秀学术论文。同时邀请国内外著名妇科专家进行专题学术讲座。现将有关事项通知如下:

一、征文内容: 1. 名老中医对妇科炎症及生殖障碍性疾病的诊疗方案及学术经验; 2. 妇科炎症及生殖障碍性疾病的中医诊治优势及其特色疗法; 3. 新技术、新疗法在诊治妇科炎症及生殖障碍性疾病中的应用及最新研究进展; 4. 医家诊治妇科炎症及生殖障碍性疾病经验挖掘与文献整理; 5. 金刚藤胶囊组方研究、药理作用及临床应用; 6. 金刚藤胶囊药效基础及安全性观察; 7. 金刚藤胶囊深层次开发思路及远景规划。

二、会议时间: 2018 年 11 月 9—11 日, 11 月 9 日 14:00 时—24:00 时报到。

三、会议地点: 湖北中核国际酒店, 地址: 湖北省武汉市蔡甸区凤凰山开发区凤凰路 1 号。

四、会议费用: 会务及培训费 1200 元 (在读研究生凭身份证及研究生证 800 元), 会议统一安排食宿, 交通及住宿费自理。

五、特别提示: 1. 妇科专业委员会理事务必参会, 不参会视为自动放弃理事资格; 2. 所有参会人员请于 10 月 10 日前以电子邮件提交参会回执, 以便安排会议资料及用房等相关事宜; 3. 会期评选优秀学术论文, 颁发“福人杯”金刚藤胶囊有奖征文一、二、三等奖奖金及证书; 4. 论文投稿截止日期: 2018 年 9 月 30 日。

六、会议负责人及联系方式: 刘丹卓, 13787132521, flkh189@163.com; 通讯地址: 410007, 湖南省长沙市雨花区韶山中路 113 号湖南中医药大学。